EP3359573A4 - ANTIBODY MARKING - Google Patents

ANTIBODY MARKING Download PDF

Info

Publication number
EP3359573A4
EP3359573A4 EP16852806.5A EP16852806A EP3359573A4 EP 3359573 A4 EP3359573 A4 EP 3359573A4 EP 16852806 A EP16852806 A EP 16852806A EP 3359573 A4 EP3359573 A4 EP 3359573A4
Authority
EP
European Patent Office
Prior art keywords
antibody marking
marking
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16852806.5A
Other languages
German (de)
French (fr)
Other versions
EP3359573A1 (en
EP3359573B1 (en
Inventor
Mohammad RASHIDIAN
Hidde L. Ploegh
Neil VASDEV
Huan Steven LIANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
General Hospital Corp
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Whitehead Institute for Biomedical Research filed Critical General Hospital Corp
Priority to EP22216826.2A priority Critical patent/EP4218833A1/en
Publication of EP3359573A1 publication Critical patent/EP3359573A1/en
Publication of EP3359573A4 publication Critical patent/EP3359573A4/en
Application granted granted Critical
Publication of EP3359573B1 publication Critical patent/EP3359573B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP16852806.5A 2015-10-01 2016-10-01 Labeling of antibodies Active EP3359573B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP22216826.2A EP4218833A1 (en) 2015-10-01 2016-10-01 Labeling of antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562236117P 2015-10-01 2015-10-01
PCT/US2016/055074 WO2017059397A1 (en) 2015-10-01 2016-10-01 Labeling of antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP22216826.2A Division EP4218833A1 (en) 2015-10-01 2016-10-01 Labeling of antibodies

Publications (3)

Publication Number Publication Date
EP3359573A1 EP3359573A1 (en) 2018-08-15
EP3359573A4 true EP3359573A4 (en) 2019-05-29
EP3359573B1 EP3359573B1 (en) 2023-01-04

Family

ID=58428000

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16852806.5A Active EP3359573B1 (en) 2015-10-01 2016-10-01 Labeling of antibodies
EP22216826.2A Pending EP4218833A1 (en) 2015-10-01 2016-10-01 Labeling of antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP22216826.2A Pending EP4218833A1 (en) 2015-10-01 2016-10-01 Labeling of antibodies

Country Status (4)

Country Link
US (2) US12048753B2 (en)
EP (2) EP3359573B1 (en)
ES (1) ES2941968T3 (en)
WO (1) WO2017059397A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131208A (en) 2013-03-13 2015-11-24 이미지냅 인코포레이티드 Antigen binding constructs to cd8
EP2994491A4 (en) 2013-05-10 2016-12-07 Whitehead Inst Biomedical Res IN VITRO PRODUCTION OF RED GLOBULES WITH PROTEINS THAT CAN BE MEDIATED BY SORTASE
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
US10556024B2 (en) 2013-11-13 2020-02-11 Whitehead Institute For Biomedical Research 18F labeling of proteins using sortases
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EA201991673A1 (en) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. LAB3-labeled RADIOACTIVE ISOTOPE ANTIBODIES FOR IMMUNO-PET VISUALIZATION
AR111837A1 (en) 2017-05-30 2019-08-21 Agrivida Inc IMMUNOMODULATING TRANSGENIC PLANTS AND RELATED METHODS
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
US11712205B2 (en) 2017-08-22 2023-08-01 Albert Einstein College Of Medicine High resolution intravital imaging and uses thereof
MX2020007442A (en) 2018-01-12 2020-09-14 Prolynx Llc Protocol for minimizing toxicity of combination dosages and imaging agent for verification.
CA3092421A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
EP3818085A4 (en) 2018-06-01 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND THEIR USES FOR TREATING A DISEASE OR CONDITION
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
EP3826673A4 (en) * 2018-07-26 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
CN113795511B (en) 2019-01-23 2024-07-23 大有华夏生物医药集团有限公司 Anti-PD-L1 double antibody and its use
EP3923974A4 (en) * 2019-02-06 2023-02-08 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USE THEREOF
BR112021022237A2 (en) 2019-05-10 2022-03-29 Janssen Biotech Inc Macrocyclic chelators and methods of using them
CN110118847B (en) * 2019-05-17 2021-08-10 重庆派金生物科技有限公司 Analysis method for determining modification sites of multi-site PEG modified protein
WO2021034924A1 (en) * 2019-08-20 2021-02-25 Biogen Ma Inc. Trans-cyclooctene labeled antisense oligonucleotides, radio labeled tetrazine and methods
TWI873176B (en) * 2019-09-04 2025-02-21 美商建南德克公司 Cd8 binding agents and uses thereof
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
EP4041297A4 (en) * 2019-10-11 2024-02-28 The Trustees of The University of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING CD13 AND TIM-3 WITH CAR-T CELLS IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
CN110755647B (en) * 2019-11-19 2022-03-15 江苏省原子医学研究所 CAR-T cell in vivo proliferation monitoring tracer, preparation method thereof and CAR-T cell in vivo proliferation quantitative method
TW202136221A (en) * 2019-12-10 2021-10-01 美商美國禮來大藥廠 Pre-targeting imaging agents
EP4073064A4 (en) * 2019-12-11 2024-01-24 The General Hospital Corporation CELL IMAGING PROCESSES
JP7605555B2 (en) * 2020-03-25 2024-12-24 積水メディカル株式会社 Immunological analysis method and immunological analysis reagent kit
TWI809597B (en) * 2020-12-16 2023-07-21 美商美國禮來大藥廠 Pretargeting imaging agents
CN113264967B (en) * 2021-05-17 2023-04-18 江苏省原子医学研究所 Programmed death ligand-1 targeted compound and preparation method and application thereof
CN119768384A (en) 2022-03-08 2025-04-04 哥本哈根大学 Methods for providing labeled single isomeric chemical entity targeting vectors based on the use of isomer-free dienophiles
AU2023375377A1 (en) * 2022-11-07 2025-05-29 Tessera Therapeutics, Inc. Lipid nanoparticle drug conjugates
WO2024158813A2 (en) * 2023-01-24 2024-08-02 Providence Health & Services - Oregon Pet tracer for detection of transforming growth factor beta
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
EP4655324A1 (en) 2023-01-27 2025-12-03 Vib Vzw Cd163-binding conjugates
EP4709753A1 (en) 2023-05-11 2026-03-18 Vib Vzw Slc4a4/nbce1 inhibitors
EP4520751A1 (en) 2023-09-05 2025-03-12 University of Copenhagen Method for rapid oxidation of dihydropyridazines to pyridazines
EP4653425A1 (en) 2024-05-21 2025-11-26 Tetrakit Technologies ApS Method for rapidly providing pyridazines from tetrazines and cis-dienophiles
DE102024129442A1 (en) 2024-10-11 2026-04-16 Universität Potsdam, Körperschaft des öffentlichen Rechts POLYMER-COUPLED ANTIBODIES AND ANTIBODIE FRAGMENTS

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
WO2010078376A2 (en) * 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
US20110195021A1 (en) * 2010-02-10 2011-08-11 Immunogen Inc. Cd20 antibodies and uses thereof
US20150086576A1 (en) * 2012-04-13 2015-03-26 Whitehead Institute For Biomedical Research Sortase-modified vhh domains and uses thereof
WO2015073746A2 (en) * 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research 18f labeling of proteins using sortases

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
DK51092D0 (en) 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5296703A (en) 1992-04-01 1994-03-22 The Regents Of The University Of California Scanning confocal microscope using fluorescence detection
ATE162198T1 (en) 1992-07-27 1998-01-15 Hybridon Inc OLIGONUCLEOTIDE ALKYLPHOSPHONOTHIATE
US5283433A (en) 1992-10-05 1994-02-01 The Regents Of The University Of California Scanning confocal microscope providing a continuous display
AU684748B2 (en) 1993-01-21 1998-01-08 Hybridon, Inc. Foldback triplex-forming oligonucleotides
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
DE69535243T2 (en) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. AGAINST HUMAN INTERLEUKIN-8 DIRECTED, RECONSTITUTED HUMAN ANTIBODY
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5955599A (en) 1995-06-01 1999-09-21 Hybridon, Inc. Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
US6140482A (en) 1995-06-01 2000-10-31 Hybridon, Inc. Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
US5614622A (en) 1995-06-01 1997-03-25 Hybridon, Inc. 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
US5637683A (en) 1995-07-13 1997-06-10 Cornell Research Foundation, Inc. Nucleic acid analog with amide linkage and method of making that analog
US5652356A (en) 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US6022688A (en) 1996-05-13 2000-02-08 Sequenom, Inc. Method for dissociating biotin complexes
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
CN1173776C (en) 1996-06-28 2004-11-03 卡钳技术有限公司 High Throughput Screening Analysis System in Microscale Fluidic Devices
WO1998008858A1 (en) 1996-08-26 1998-03-05 Hybridon, Inc. Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages
US5886165A (en) 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6133436A (en) 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
US5900481A (en) 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US6447727B1 (en) 1996-11-19 2002-09-10 Caliper Technologies Corp. Microfluidic systems
US6090919A (en) 1997-01-31 2000-07-18 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
WO1998033809A1 (en) 1997-01-31 1998-08-06 The General Hospital Corporation Compositions and methods for imaging gene expression
US6235471B1 (en) 1997-04-04 2001-05-22 Caliper Technologies Corp. Closed-loop biochemical analyzers
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
US6100541A (en) 1998-02-24 2000-08-08 Caliper Technologies Corporation Microfluidic devices and systems incorporating integrated optical elements
US6455263B2 (en) 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
US6461813B2 (en) 1998-09-21 2002-10-08 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in cell cycle regulation
EP1233780A4 (en) 1999-04-15 2004-09-22 Univ California IDENTIFICATION OF THE SORTASEGEN
US7101692B2 (en) 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
US6342219B1 (en) 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6451602B1 (en) 2000-03-02 2002-09-17 Isis Pharmaceuticals, Inc. Antisense modulation of PARP expression
CA2413538A1 (en) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions and methods for preparation thereof
US7279304B2 (en) 2000-12-18 2007-10-09 President And Fellows Of Harvard College Methods for preparation of macrocyclic molecules and macrocyclic molecules prepared thereby
US6451538B1 (en) 2000-12-22 2002-09-17 Isis Pharmaceuticals, Inc. Antisense modulation of CHK2 expression
US6455307B1 (en) 2001-02-08 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-alpha prime expression
US6455308B1 (en) 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
AU2002357932A1 (en) 2001-12-18 2003-06-30 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
US6960473B2 (en) 2003-02-27 2005-11-01 Istituto Superiore Di Sanita In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients
DE10335584B4 (en) 2003-07-31 2006-06-29 Philipps-Universität Marburg Process for the preparation of cyclic molecules
WO2005051976A2 (en) 2003-11-20 2005-06-09 Ansata Therapeutics, Inc. Protein and peptide ligation processes and one-step purification processes
US20090098611A1 (en) 2004-02-27 2009-04-16 Wood David W Self-cleaving affinity tags and methods of use
EP1753859B1 (en) 2004-06-04 2014-07-30 Université Pierre et Marie Curie (Paris 6) A method for producing red blood cells
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
WO2007108013A2 (en) 2006-03-22 2007-09-27 National Institute Of Immunology Novel bioconjugates as therapeutic agent and synthesis thereof
US8398956B2 (en) * 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
WO2008148143A1 (en) 2007-06-06 2008-12-11 University Of Wollongong Diagnostics in a monoplex/multiplex format
BR122017025062B8 (en) 2007-06-18 2021-07-27 Merck Sharp & Dohme monoclonal antibody or antibody fragment to human programmed death receptor pd-1, polynucleotide and composition comprising said antibody or fragment
US8865875B2 (en) * 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20110070154A1 (en) 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
JP2012500855A (en) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド PD-1 antagonists and methods for treating infectious diseases
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
JP2010115136A (en) 2008-11-12 2010-05-27 Teruyuki Nagamune Method for creating membrane protein with labelled n-terminal end, and cell having membrane protein with labelled n-terminal end in its outer layer
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
JP5844159B2 (en) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ PD-1 antibody and PD-L1 antibody and use thereof
PL2539441T3 (en) 2010-02-22 2017-06-30 Université Pierre Et Marie Curie (Paris 6) Cell culture medium for the growth and differentiation of cells of the hematopoietic lineage
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
WO2011133704A2 (en) 2010-04-20 2011-10-27 Whitehead Institute For Biomedical Researh Modified polypeptides and proteins and uses thereof
US10434197B2 (en) 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
AU2012275390A1 (en) 2011-06-28 2014-01-16 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
PE20141522A1 (en) 2011-08-17 2014-11-17 Glaxo Group Ltd PROTEINS AND MODIFIED PEPTIDES
CN102559600A (en) 2011-12-29 2012-07-11 上海交通大学医学院 Artificial antigen presenting cell and application thereof in NK (natural killer) cell amplification
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
US20140030697A1 (en) 2012-06-14 2014-01-30 Massachusetts Institute Of Technology Sortase-mediated modification of viral surface proteins
US9267127B2 (en) 2012-06-21 2016-02-23 President And Fellows Of Harvard College Evolution of bond-forming enzymes
US9511350B2 (en) * 2013-05-10 2016-12-06 Clean Diesel Technologies, Inc. (Cdti) ZPGM Diesel Oxidation Catalysts and methods of making and using same
EP2994491A4 (en) 2013-05-10 2016-12-07 Whitehead Inst Biomedical Res IN VITRO PRODUCTION OF RED GLOBULES WITH PROTEINS THAT CAN BE MEDIATED BY SORTASE
WO2014183066A2 (en) 2013-05-10 2014-11-13 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
WO2015051188A1 (en) * 2013-10-02 2015-04-09 Washington University Heterocyclic molecules for biomedical imaging and therapeutic applications
US9878045B2 (en) 2013-10-15 2018-01-30 Regents Of The University Of Minnesota Triorthogonal reagents for dual protein conjugation
GB201417386D0 (en) 2014-10-01 2014-11-12 Nofima As Sugar-depleted fruit or vegetable juice product, method of producing the same and use thereof to maintain health and treat and to prevent medical ailments
US10053683B2 (en) 2014-10-03 2018-08-21 Whitehead Institute For Biomedical Research Intercellular labeling of ligand-receptor interactions
CA3141315A1 (en) 2019-05-24 2020-12-03 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
WO2010078376A2 (en) * 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
US20110195021A1 (en) * 2010-02-10 2011-08-11 Immunogen Inc. Cd20 antibodies and uses thereof
US20150086576A1 (en) * 2012-04-13 2015-03-26 Whitehead Institute For Biomedical Research Sortase-modified vhh domains and uses thereof
WO2015073746A2 (en) * 2013-11-13 2015-05-21 Whitehead Institute For Biomedical Research 18f labeling of proteins using sortases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017059397A1 *

Also Published As

Publication number Publication date
ES2941968T3 (en) 2023-05-29
EP3359573A1 (en) 2018-08-15
US20180280551A1 (en) 2018-10-04
US20240325575A1 (en) 2024-10-03
WO2017059397A1 (en) 2017-04-06
EP3359573B1 (en) 2023-01-04
EP4218833A1 (en) 2023-08-02
US12048753B2 (en) 2024-07-30

Similar Documents

Publication Publication Date Title
EP3359573A4 (en) ANTIBODY MARKING
MA49034A (en) ANTI-LAG3 ANTIBODY
MA47694A (en) ANTI-TIGIT ANTIBODY
EP3498840A4 (en) ANTI-LAG-3 ANTIBODIES
MA47268A (en) ANTIBODY ANTI-GPC3
EP3423089A4 (en) ANTI-TIGIT ANTIBODIES
MA44381A (en) MULTISPECIFIC HETERODIMERIC ANTIBODY FORMAT
EP3430731A4 (en) IUGW ARCHITECTURE
MA44236A (en) ANTI-TGFBETA ANTIBODY 2
MA46041A (en) ANTI-BODY ANTI-TIM -3
EP3334757A4 (en) ANTI-TIGIT ANTIBODIES
EP3297671A4 (en) ANTI-ROR1 ANTIBODIES
MA45004A (en) ANTI-WT1-HLA SPECIFIC ANTIBODIES
EP3492591A4 (en) ANTI-B7-H4 ANTIBODIES
EP3526247A4 (en) ANTI-IL1-RAP ANTIBODIES
EP3443293A4 (en) EFFORT SENSORS
EP3617231A4 (en) ANTI-GPC-1 ANTIBODY
EP3484919A4 (en) ANTI-BETA-AMYLOID ANTIBODIES
EP3399992A4 (en) AUTORESTICULANT ANTIBODIES
MA51134A (en) ANTI-ALPHA-SYNUCLEIN ANTIBODY
MA42843A (en) ANTI-CD115 ANTIBODY
EP3336185A4 (en) ANTIBODY
MA51135A (en) ANTI-ALPHA-SYNUCLEIN ANTIBODY
EP3381941A4 (en) ANTI-EPHA4 ANTIBODIES
EP3482698A4 (en) HEMOSTASE INSTRUMENT

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602016077323

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07K0016280000

Ipc: A61K0051100000

A4 Supplementary search report drawn up and despatched

Effective date: 20190429

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 51/10 20060101AFI20190423BHEP

Ipc: G01N 33/58 20060101ALI20190423BHEP

Ipc: C12P 21/00 20060101ALI20190423BHEP

Ipc: C07K 16/28 20060101ALI20190423BHEP

Ipc: C07K 16/46 20060101ALI20190423BHEP

Ipc: A61P 35/00 20060101ALI20190423BHEP

Ipc: A61K 39/00 20060101ALI20190423BHEP

Ipc: C07K 16/24 20060101ALI20190423BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200403

INTG Intention to grant announced

Effective date: 20220711

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20221125

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016077323

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1541486

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2941968

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20230529

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNGEN

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1541486

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230104

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

RIN2 Information on inventor provided after grant (corrected)

Inventor name: PLOEGH, HIDDE L.

Inventor name: RASHIDIAN, MOHAMMAD

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230504

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230404

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602016077323

Country of ref document: DE

Owner name: THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARC, US

Free format text: FORMER OWNERS: THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA, US; THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, CAMBRIDGE, MA, US

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230504

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230405

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016077323

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

Effective date: 20231010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

26N No opposition filed

Effective date: 20231005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20161001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20161001

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251101

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20251026

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230104

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251029

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251027

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20251021

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251027

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20251027

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20251101

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20251027

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251103

Year of fee payment: 10